How to analyse an Indian pharma stock: the framework every investor needs

The two-engine pharma model: domestic versus exports

Indian pharma companies broadly operate two business engines. The domestic branded formulations business sells prescription and over-the-counter medicines under proprietary brands through the Indian distribution network. This business enjoys relatively stable margins, low regulatory risk, and pricing power driven by brand equity and physician relationships. Top domestic formulation companies include Sun Pharma, Cipla, Dr Reddy's, Lupin, and Torrent Pharma.

The US generics export business is fundamentally different: companies file Abbreviated New Drug Applications (ANDAs) with the USFDA to sell off-patent versions of branded US drugs at lower prices. This business is volume-driven, margin-pressured by competition from multiple generic filers, and exposed to USFDA manufacturing inspection risk. A single import alert or warning letter from USFDA on an Indian manufacturing site can remove a company from the US market for months or years, causing severe revenue shortfalls. Investors must treat domestic formulations and US generics as distinct risk-return profiles within the same company.

USFDA compliance: the make-or-break variable

USFDA regulatory compliance is the single most important risk factor for Indian pharma companies with US exports. USFDA inspects manufacturing plants that supply the US market, evaluating Good Manufacturing Practice (GMP) compliance across areas including documentation, contamination controls, equipment validation, and quality systems. An Observation 483 (inspection findings) is a notice requiring corrective action. A Warning Letter is a more severe finding that effectively freezes new product approvals from that facility until resolved. An Import Alert is the most severe outcome: it blocks shipments from a specific plant, directly removing revenue.

Companies with multiple manufacturing sites can absorb a single site's warning letter by shifting production. Single-facility operations face existential revenue risk from a USFDA action. When analysing a pharma stock, investors should check the current USFDA inspection history on the FDA's public database, count how many of the company's revenue-generating plants have received 483s or warning letters in the preceding three years, and assess management's track record in resolving prior observations. A company that has repeatedly received and resolved USFDA observations has demonstrated operational resilience. One that has never received an adverse finding may be due for scrutiny - or may genuinely have world-class quality systems.

US generics price erosion and domestic margin trajectory

US generic drug prices erode structurally as more manufacturers obtain approval to sell the same molecule. The rate of price erosion varies: highly competitive molecules with six or more approved filers erode at 10 to 20 percent annually. First-to-file exclusivities - 180-day market exclusivity for the first generic filer - allow companies to earn significantly above-market margins before competition enters. A company with a strong pipeline of first-to-file ANDAs has built-in margin protection in its US generics business.

Domestic branded formulations typically carry EBITDA margins between 20 and 30 percent for well-run companies. US-generics-heavy companies often have lower consolidated EBITDA margins (16 to 22 percent) because US pricing is competitive. Contract development and manufacturing organisations (CDMOs) - companies like Divi's Laboratories and Laurus Labs that manufacture intermediates and APIs for global innovators - have their own margin profile driven by order backlog, capacity utilisation, and client concentration. When evaluating valuation, compare the company to peers within the same sub-segment rather than to the sector as a whole.

FAQ2 reader questions · AEO-eligible

Common questions on how to analyse a pharma stock.

Keep learning

Adjacent concepts every Indian retail investor should have straight.